Nuclear Antigen Antikörper
Kurzübersicht für Nuclear Antigen Antikörper (ABIN4889449)
Target
Alle Nuclear Antigen (IPO-38) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
- 
    - 
                                            Spezifität
- Reacts with human Proliferation Marker IPO-38. This antigen was detected after 12 h of PHA-induced activation in the early G1 phase but absent in non-stimulated lymphocytes.
- 
                                            Aufreinigung
- Purified (protein A)
- 
                                            Immunogen
- Spleen cells of a human patient with hairy cell leukemia.
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        Working dilution: Optimal dilutions should be determined by the end user.
 The following are guidelines only:
 ELISA (1:10000 - 1:50000) IHC - F, IHC - P (10 μg/mL) IP, WB (1:500 - 1:2000)
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Buffer
- 0.02 M potassium phosphate, 0.5 M NaCl, pH 7.2
- 
                                            Konservierungsmittel
- Sodium azide
- 
                                            Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Lagerung
- -20 °C
- 
                                            Informationen zur Lagerung
- Long term: -20°C, Short term: -20°C
 
- 
                                            
- 
    - Nuclear Antigen (IPO-38)
- 
                                            Andere Bezeichnung
- Proliferation Marker IPO-38
 Target
- 
                    
 
                                     
                                     
                                    